LivaNova PLC Announces Chief Financial Officer Resignation
March 31 2017 - 9:00AM
Business Wire
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the
“Company”), a market-leading medical technology and innovation
company, today announced its Chief Financial Officer, Vivid Sehgal,
is leaving the company to pursue other opportunities. The company
has an external search underway to identify a replacement. Sehgal
will continue as CFO and will support an orderly transition to his
successor.
“Vivid has been the company’s CFO since its inception in October
2015 and has been an integral part of our Executive Leadership
team,” said Damien McDonald, LivaNova’s Chief Executive Officer.
“His leadership, insights and guidance have been instrumental in
building a strong team, while establishing financial disciplines
across the portfolio. His presence, knowledge and leadership will
be important through the transition period. We wish to thank him
for his many contributions in helping to position the company for
sustainable growth.”
“I have a number of things I wish to do, not the least of which
will be spending more time with family and pursuing personal
interests,” said Vivid Sehgal, LivaNova’s CFO. “I am very proud of
what we have accomplished for our employees and shareowners in a
short time as a new public company. We made progress in critical
areas, including achieving merger-related synergies, restructuring,
capital formation, cost controls and building a sustainable tax
strategy. I remain fully committed to helping Damien and the
LivaNova team with this important transition.”
About LivaNova
LivaNova PLC is a global medical technology company built on
nearly five decades of experience and a relentless commitment to
improve the lives of patients around the world. LivaNova’s advanced
technologies and breakthrough treatments provide meaningful
solutions for the benefit of patients, healthcare professionals and
healthcare systems. Headquartered in London and with a presence in
more than 100 countries worldwide, the company employs more than
4,500 employees. LivaNova operates as three business
franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm
Management, with operating headquarters in Mirandola
(Italy), Houston (U.S.A.) and Clamart (France),
respectively.
For more information, please visit
www.LivaNova.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170331005358/en/
LivaNova PLC Investor Relations and MediaKaren
King, +1 281-228-7262Vice President, Investor Relations &
Corporate CommunicationsorDeanna Wilke, +1
281-727-2764Corporate External Communications
ManagerCorporate.Communications@LivaNova.com
Livanova (LSE:LIVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Livanova (LSE:LIVN)
Historical Stock Chart
From Apr 2023 to Apr 2024